UA107675C2 - Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом - Google Patents

Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом

Info

Publication number
UA107675C2
UA107675C2 UAA201204585A UAA201204585A UA107675C2 UA 107675 C2 UA107675 C2 UA 107675C2 UA A201204585 A UAA201204585 A UA A201204585A UA A201204585 A UAA201204585 A UA A201204585A UA 107675 C2 UA107675 C2 UA 107675C2
Authority
UA
Ukraine
Prior art keywords
treatment
thienyl
oxy
phenyl
amino
Prior art date
Application number
UAA201204585A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Marc Payton
Richard Kendall
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA107675(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UA107675C2 publication Critical patent/UA107675C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201204585A 2009-09-11 2010-09-09 Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом UA107675C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24152709P 2009-09-11 2009-09-11
PCT/US2010/048247 WO2011031842A1 (en) 2009-09-11 2010-09-09 N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Publications (1)

Publication Number Publication Date
UA107675C2 true UA107675C2 (xx) 2015-02-10

Family

ID=43216900

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201204585A UA107675C2 (xx) 2009-09-11 2010-09-09 Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом

Country Status (34)

Country Link
US (1) US20120028917A1 (https=)
EP (2) EP2475368B1 (https=)
JP (1) JP5851403B2 (https=)
KR (1) KR20120082896A (https=)
CN (1) CN102869361A (https=)
AU (1) AU2010292225C1 (https=)
BR (1) BR112012008325A2 (https=)
CA (1) CA2773838C (https=)
CL (1) CL2012000640A1 (https=)
CR (1) CR20120171A (https=)
DK (1) DK2475368T3 (https=)
EA (1) EA020526B1 (https=)
ES (1) ES2528485T3 (https=)
HK (1) HK1205457A1 (https=)
HR (1) HRP20150104T1 (https=)
HU (1) HUE024568T2 (https=)
IL (1) IL218569A0 (https=)
MA (1) MA33658B1 (https=)
ME (1) ME02048B (https=)
MX (1) MX2012003041A (https=)
NZ (1) NZ598758A (https=)
PE (1) PE20120895A1 (https=)
PH (1) PH12012500504A1 (https=)
PL (1) PL2475368T3 (https=)
PT (1) PT2475368E (https=)
RS (1) RS53807B1 (https=)
SG (1) SG179102A1 (https=)
SI (1) SI2475368T1 (https=)
SM (1) SMT201500028B (https=)
TN (1) TN2012000110A1 (https=)
TW (1) TW201121956A (https=)
UA (1) UA107675C2 (https=)
WO (1) WO2011031842A1 (https=)
ZA (1) ZA201202472B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518053A (ja) * 2012-05-31 2015-06-25 アムジエン・インコーポレーテツド 癌の治療のためのａｍｇ９００の使用
CN103664737A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
US9963701B2 (en) 2013-09-30 2018-05-08 Korea Institute Of Radiological & Medical Sciences Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising HRP-3 inhibitor
HRP20220718T1 (hr) 2013-11-11 2022-09-30 Amgen Inc. Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka
US10053452B2 (en) 2013-12-03 2018-08-21 Amgen Inc. Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof
SG11201606869TA (en) * 2014-02-21 2016-09-29 Frost Biolog Inc Antimitotic amides for the treatment of cancer and proliferative disorders
CN109313197A (zh) * 2016-04-15 2019-02-05 费利克斯疗法公司 使用静止细胞靶向和有丝分裂抑制剂的用于治疗肿瘤的组合
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
MA50077A (fr) 2017-09-08 2020-07-15 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US20190375749A1 (en) 2018-06-11 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
ES3060664T3 (en) 2018-06-12 2026-03-27 Amgen Inc Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
NZ782284A (en) 2019-05-21 2024-11-29 Amgen Inc Solid state forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178318A1 (en) * 2003-07-03 2006-08-10 Shubha Anand Use of aurora kinase inhibitors for reducing the resistance of cancer cells
AU2007208351C1 (en) * 2006-01-23 2011-07-07 Amgen Inc. Aurora kinase modulators and method of use
UA93538C2 (en) * 2006-01-23 2011-02-25 Амген Инк. Aurora kinase modulators and method of use
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination

Also Published As

Publication number Publication date
AU2010292225C1 (en) 2013-06-27
EP2818170B1 (en) 2018-12-05
EP2818170A1 (en) 2014-12-31
JP2013504582A (ja) 2013-02-07
EA201270383A1 (ru) 2013-04-30
CA2773838A1 (en) 2011-03-17
IL218569A0 (en) 2012-05-31
RS53807B1 (sr) 2015-06-30
JP5851403B2 (ja) 2016-02-03
PE20120895A1 (es) 2012-08-19
CR20120171A (es) 2012-08-09
PL2475368T3 (pl) 2015-05-29
TN2012000110A1 (en) 2013-09-19
TW201121956A (en) 2011-07-01
NZ598758A (en) 2013-12-20
WO2011031842A1 (en) 2011-03-17
HRP20150104T1 (xx) 2015-03-13
US20120028917A1 (en) 2012-02-02
MA33658B1 (fr) 2012-10-01
MX2012003041A (es) 2012-06-27
CA2773838C (en) 2016-05-31
EP2475368A1 (en) 2012-07-18
SI2475368T1 (sl) 2015-03-31
EP2475368B1 (en) 2014-12-17
HK1173655A1 (en) 2013-05-24
EA020526B1 (ru) 2014-11-28
ZA201202472B (en) 2012-12-27
AU2010292225A1 (en) 2012-04-12
DK2475368T3 (en) 2015-03-09
PT2475368E (pt) 2015-02-10
ME02048B (me) 2015-05-20
KR20120082896A (ko) 2012-07-24
HK1205457A1 (en) 2015-12-18
HUE024568T2 (hu) 2016-02-29
ES2528485T3 (es) 2015-02-10
CN102869361A (zh) 2013-01-09
PH12012500504A1 (en) 2015-04-29
SG179102A1 (en) 2012-04-27
CL2012000640A1 (es) 2012-09-21
BR112012008325A2 (pt) 2017-08-29
AU2010292225B2 (en) 2012-12-13
SMT201500028B (it) 2015-03-05

Similar Documents

Publication Publication Date Title
UA107675C2 (xx) Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
UA94129C2 (ru) Соединения для ингибирования митоза
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
AU2011297889A8 (en) Pharmaceutically active compounds as Axl inhibitors
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
EA200971115A1 (ru) Новые ингибиторы обратной транскриптазы вич
EA201001687A1 (ru) Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 )
WO2009155121A3 (en) Inhibitors of pi3 kinase
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
UA108369C2 (uk) Піролопіримідини як інгібітори cdk4/6
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
MY150214A (en) Kinesin inhibitors as cancer therapeutics
ATE542800T1 (de) Kinasehemmer und ihre anwendungsverfahren
MX2014005715A (es) N-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]- benzamida para el tratamiento de leucemia mielogenosa cronica.
GEP20146025B (en) Chromenone derivatives as trpv3 antagonists
MY150776A (en) Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria
ATE548364T1 (de) Aminopyrazolkinasehemmer
NZ738247A (en) 4-(3-pyrazolylamino)-benzimidazole compounds and their use as jak1 inhibitors
MX2015015290A (es) Compuestos furanona como inhibidores de quinasa.
CY1115851T1 (el) Ν-4(-((3-(2-αμινο-4 πυριμιδινυλ)-2-πυριδινυλ)οξυ)φαινυλ)-4-(4-μεθυλ-2-θειενυλ)-1-φθαλαζιναμινη για χρηση στη θεραπεια ανθεκτικου σε αντιμιτωτικο παραγοντα καρκινου